Coronary disease & ACSSecondary analysis

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk

JAMA CardiolPublished

  • Prespecified subgroup analysis of the MASTER dual antiplatelet therapy (DAPT) randomised trial
  • multicentre
  • open-label
  • 140 sites in 30 countries

Authors' conclusion

These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events.

Study context

Population
Patients at high bleeding risk randomised 1 month after percutaneous coronary intervention (PCI)1,408 women · 3,171 men
Participants
4,579 patients
Comparison
Abbreviated vs standard DAPT, by sex
Primary endpoint
NACE (death, MI, stroke or major bleeding), MACCE (death, MI or stroke) and major or clinically relevant nonmajor bleeding (MCB)
Follow-up
1 year

Primary result

As reported in the abstract

NACE by sex
Abbreviated DAPT vs Standard DAPTHazard ratio (95% CI)
men
0.97(0.75–1.24)
women
0.87(0.60–1.26)

Further findings

MACCE by sex (subgroup) · 1 year

Women: trend toward benefit with abbreviated vs standard DAPT, HR
0.68 (95% CI 0.44-1.05)
Men: no benefit with abbreviated vs standard DAPT, HR
1.17 (95% CI 0.88-1.55)
  • heterogeneity of treatment effect by sex
  • P = .04 for interaction

NACE, MACCE and MCB in patients with ACS and/or complex PCI

Results remained consistent

Safety

OutcomeHR (95% CI)
MCB by sex · 1 year — Abbreviated DAPT vs Standard DAPT · men0.65 (0.50–0.84)
MCB by sex · 1 year — Abbreviated DAPT vs Standard DAPT · women0.77 (0.53–1.12)
  • MCB by sex: P = .46 for interaction

Original publication

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk. JAMA Cardiol. Published 1 January 2024. doi:10.1001/jamacardio.2023.4316

Summarised from the published abstract; every number is checked against it